Login
Register
Submit a Paper
Propose a Special lssue
Open Access
ARTICLE
Low and intermediate risk prostate cancer – role of hormonal therapy with external beam radiation therapy
Department of Radiation Oncology, University of Toronto and Radiation Medicine Program, Princess Margaret Hospital, Toronto,
Ontario, Canada
Address correspondence to Dr. Padraig Warde, Department
of Radiation Oncology, Princess Margaret Hospital, 610
University Avenue, Toronto, Ontario M5G 2M9 Canada
Canadian Journal of Urology 2006, 13(Suppl.2), 63-67.
Download PDFAbstract
Risk categorization based on pre-treatment PSA, clinical stage and Gleason score is now widely used in the management of patients with localized prostate cancer. In patients with low-risk disease (cT1-T2a, PSA < 10 ng/ml and Gleason score ≤ 6) there is no role for the routine use of adjunctive hormonal therapy. In intermediate-risk patients (T1-T2, PSA < 20 ng/ml and Gleason ≤ 7) there is some evidence to suggest improved outcomes with neo-adjuvant hormonal therapy when low-dose external beam radiation therapy (EBRT) is used. However, with appropriate modern dose EBRT there is little data to support the use of routine adjunctive hormonal therapy and this should be done only in the context of a clinical trial.Keywords
prostate cancer, radiation therapy, hormones, risk categorization
Cite This Article
APA Style
Martin, J., Bristow, R., Warde, P. (2006). Low and intermediate risk prostate cancer – role of hormonal therapy with external beam radiation therapy. Canadian Journal of Urology, 13(Suppl.2), 63–67.
Vancouver Style
Martin J, Bristow R, Warde P. Low and intermediate risk prostate cancer – role of hormonal therapy with external beam radiation therapy. Can J Urology. 2006;13(Suppl.2):63–67.
IEEE Style
J. Martin, R. Bristow, and P. Warde, “Low and intermediate risk prostate cancer – role of hormonal therapy with external beam radiation therapy,” Can. J. Urology, vol. 13, no. Suppl.2, pp. 63–67, 2006.
Copyright © 2006 The Author(s). Published by Tech Science Press.This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Downloads
Citation Tools
